Joshua K. Sabari
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
Resistance Mechanisms in Small Cell Lung Cancer
Open Date: 2016-07-01
Close Date: 2018-07-01
Articles (32)
Amivantamab is a fully human bispecific epidermal growth factor receptor (EGFR)–directed and mesenchymal epithelial transition (MET) receptor–directed antibody. Intravenous amivantamab is approved and recommended by treatment guidelines as a first-line treatment (1L) in combination with lazertinib, as a second-line treatment (2L) in combination with chemotherapy in adults with advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, and as 2L monotherapy or 1L in combination with chemotherapy in adults with advanced or metastatic NSCLC with exon 20 insertion-mutations. Compared with previous therapies, novel treatments such as amivantamab may be associated with distinct and unique adverse reactions that potentially require optimized prevention and management techniques. Commonly reported adverse reactions associated with amivantamab treatment regimens include cutaneous reactions associated with EGFR inhibition, such as rash, paronychia, and pruritus; those associated with MET inhibition, such as peripheral edema and hypoalbuminemia; and general effects, such as infusion-related reactions. Recommendations are summarized from published guidelines and the authors’ clinical experience for the prevention and management of adverse reactions associated with amivantamab. An understanding of the expected adverse events with amivantamab regimens, along with the range of prophylactic and management options available, may facilitate maintenance of ongoing treatment in patients deriving clinical benefit and improve patient quality of life on therapy.
Year:
2025
Adagrasib, an irreversible, selective KRAS G12C inhibitor, may be an effective treatment in KRAS G12C -mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRAS G12C -mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRAS G12C -mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRAS G12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4
Year:
2024
Table S3. Efficacy summary per BICR with adagrasib plus cetuximab in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC, overall, and in phase 1 and phase 2 cohorts.
Year:
2024
Table S3. Efficacy summary per BICR with adagrasib plus cetuximab in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC, overall, and in phase 1 and phase 2 cohorts.
Year:
2024
Supplementary Figure S1. Changes from baseline in sum of target lesion diameters over time for patients continuing treatment after progression, either with adagrasib plus cetuximab (n = 38), adagrasib only (n = 10), or cetuximab only (n = 1). Only patients with available post-progression scans are included in the plot (n = 33 for adagrasib plus cetuximab; n = 1 for adagrasib only).
Year:
2024
Supplementary Figure S1. Changes from baseline in sum of target lesion diameters over time for patients continuing treatment after progression, either with adagrasib plus cetuximab (n = 38), adagrasib only (n = 10), or cetuximab only (n = 1). Only patients with available post-progression scans are included in the plot (n = 33 for adagrasib plus cetuximab; n = 1 for adagrasib only).
Year:
2024
Table S3. Efficacy summary per BICR with adagrasib plus cetuximab in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC, overall, and in phase 1 and phase 2 cohorts.
Year:
2024
Supplementary Figure S1. Changes from baseline in sum of target lesion diameters over time for patients continuing treatment after progression, either with adagrasib plus cetuximab (n = 38), adagrasib only (n = 10), or cetuximab only (n = 1). Only patients with available post-progression scans are included in the plot (n = 33 for adagrasib plus cetuximab; n = 1 for adagrasib only).
Year:
2024
Adagrasib, an irreversible, selective KRAS G12C inhibitor, may be an effective treatment in KRAS G12C -mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRAS G12C -mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRAS G12C -mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRAS G12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4
Year:
2024
Table S3. Efficacy summary per BICR with adagrasib plus cetuximab in previously treated patients with KRASG12C-mutated unresectable or metastatic CRC, overall, and in phase 1 and phase 2 cohorts.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (5)
Scott E. Kopetz
The University of Texas MD Anderson Cancer Center
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Tanios Bekaii-Saab
Mayo Clinic
Beth N. McLellan
Albert Einstein College of Medicine
Nataliya Uboha
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.